Research graph
References from OCT angiography and structural biomarker outcomes of faricimab versus aflibercept in treatment-naïve polypoidal choroidal vasculopathy. Local targets link to admitted publications; unresolved targets remain external evidence.
Polypoidal choroidal vasculopathy: an update on diagnosis and treatment
10.2147/opth.s385827 · 2023 · External reference
Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management
10.1016/j.ophtha.2017.11.019 · 2018 · External reference
PLANET investigators, efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial
10.1001/jamaophthalmol.2018.1804 · 2018 · External reference
Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis
10.1111/aos.16797 · 2025 · External reference
Design and rationale of the SALWEEN Trial: a phase 3b/4 study of faricimab, a dual angiopoietin-2 and vascular endothelial growth factor-A inhibitor, in Patients With Polypoidal Choroidal
2025 · External reference
One-year outcomes of faricimab versus aflibercept treatment for polypoidal choroidal vasculopathy: a comparative study
10.1038/s41433-025-03980-2 · 2025 · External reference
Early anatomical outcomes of faricimab vs aflibercept 2 mg in treatment-naïve neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: a head-to-head comparative study in Taiwan
10.1097/jcma.0000000000001320 · 2026 · External reference
Impact of photodynamic therapy combined with Anti-VEGF vs. Anti-VEGF monotherapy on choriocapillaris vessel density in polypoidal choroidal vasculopathy
10.1016/j.pdpdt.2025.104531 · 2025 · External reference
Choroidal changes in eyes with polypoidal Choroidal vasculopathy after anti-VEGF therapy imaged with swept-source OCT angiography
10.1167/iovs.62.15.5 · 2021 · External reference
Polypoidal choroidal vasculopathy: a comprehensive clinical update
10.1177/2515841419831152 · 2019 · External reference
Survival benefit of postoperative chemotherapy in stage III lung squamous cell carcinoma based on SEER database analysis through propensity score matching
10.1038/s41598-025-07766-0 · 2025 · External reference
Anatomic outcomes with Faricimab vs Aflibercept in head-to-head dosing phase of the TENAYA/LUCERNE trials in neovascular age-related macular degeneration
10.1016/j.ophtha.2024.11.023 · 2025 · External reference
Polypoidal choroidal Vasculopathy: from clinicopathological and molecular perspectives
10.1159/000548709 · 2025 · External reference
Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data
10.1038/s41433-020-01377-x · 2021 · External reference
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
10.15252/emmm.201910666 · 2019 · External reference
Diabetic Retinopathy Research Group Vienna, optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema
10.1016/j.ophtha.2008.12.039 · 2009 · External reference
Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration
10.1126/sciadv.aau6732 · 2019 · External reference
Analysis of Choriocapillaris reperfusion topography following Faricimab treatment for neovascular age-related macular degeneration in therapy-naïve patients
10.1007/s40123-024-00967-2 · 2024 · External reference
Image artifacts in optical coherence angiography
10.1097/iae.0000000000000765 · 2015 · External reference
Artifacts and artifact removal in optical coherence tomographic angiography
10.21037/qims-20-730 · 2020 · External reference
